Live Breaking News & Updates on Nasdaq Mygn

Stay updated with breaking news from Nasdaq mygn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Myriad Genetics (NASDAQ:MYGN) Posts Earnings Results, Beats Expectations By $0.05 EPS

Myriad Genetics (NASDAQ:MYGN – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.05, Briefing.com reports. The company had revenue of $191.90 million for the quarter, compared to analysts’ expectations of $179.23 million. Myriad Genetics had a […] ....

United States , New Zealand General , New Zealand , Richard Bryan Riggsbee , Wellington Management Group , America Corp , Vanguard Group Inc , Genetics Inc , Blackrock Inc , Goldman Sachs Group , Jpmorgan Chase Co , Myriad Genetics , Get Free Report , Bryan Riggsbee , Management Group , Street Corp , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily , Nasdaq Mygn ,

Myriad Genetics (NASDAQ:MYGN) Price Target Lowered to $14.00 at JPMorgan Chase & Co.

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective decreased by equities researchers at JPMorgan Chase & Co. from $17.00 to $14.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of 21.30% […] ....

United States , Richard Bryan Riggsbee , Glenview Capital Management , Goldman Sachs Group , Sei Investments Co , Oppenheimer Co , Jpmorgan Chase Co , Genetics Inc , Securities Exchange Commission , Myriad Genetics , Get Free Report , Bryan Riggsbee , Exchange Commission , State Employees Retirement System , Capital Management , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily , Nasdaq Mygn , Lower Price Target , Jpmorgan Chase Co ,

Myriad Genetics (NASDAQ:MYGN) Downgraded by StockNews.com

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday. Several other analysts also recently issued reports on MYGN. JPMorgan Chase & Co. decreased their target price on Myriad Genetics from $18.00 to $17.00 and […] ....

United States , Goldman Sachs Group , Proshare Advisors , Royal Bank , Jpmorgan Chase Co , Pricet Rowe Associates Inc , Us Bancorp , Genetics Company Profile , Genetics Inc , Ameritas Investment Partners Inc , Myriad Genetics , Get Free Report , Investment Partners , Share Advisors , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily , Nasdaq Mygn , Stocknews Com ,

Analysts Set Myriad Genetics, Inc. (NASDAQ:MYGN) PT at $24.20

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have been assigned a consensus rating of “Hold” from the five analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the […] ....

United States , Wealth Management , Genetics Company Profile , Mirae Asset Global Investments Co , Goldman Sachs Group , Genetics Inc , Sg Americas Securities , Jpmorgan Chase Co , Myriad Genetics , Get Free Report , Asset Global Investments , Get Free , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily , Nasdaq Mygn ,

Myriad Genetics (NASDAQ:MYGN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Myriad Genetics (NASDAQ:MYGN – Free Report) in a report issued on Thursday morning. The brokerage issued a hold rating on the stock. Several other equities research analysts have also issued reports on the company. JPMorgan Chase & Co. dropped their price objective on Myriad Genetics from $18.00 to $17.00 […] ....

United States , Goldman Sachs Group , Pricet Rowe Associates Inc , Proshare Advisors , Us Bancorp , Genetics Inc , Jpmorgan Chase Co , Royal Bank , Ameritas Investment Partners Inc , Myriad Genetics , Free Report , Get Free Report , Investment Partners , Share Advisors , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily , Nasdaq Mygn , Initiated Coverage , Stocknews Com ,